<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289562</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1777-Bi-04-106</org_study_id>
    <nct_id>NCT00289562</nct_id>
  </id_info>
  <brief_title>Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride&#xD;
      Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use&#xD;
      of Forodesine Hydrochloride&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride (BCX-1777)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented B-cell acute lymphoblastic leukemia (B-ALL), which under WHO Guidelines is&#xD;
             now referred to as precursor B-lymphoblastic leukemia/lymphoma&#xD;
&#xD;
          -  Must have failed at least 1 treatment regimen for B-ALL, which under WHO Guidelines is&#xD;
             now referred to as precursor B-lymphoblastic leukemia/lymphoma&#xD;
&#xD;
          -  Performance status of â‰¤2 by Eastern Cooperative Oncology Group (ECOG) criteria&#xD;
&#xD;
          -  Any age is allowed&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase&#xD;
             [ALT] not &gt;3 times upper limits of normal [ULN])&#xD;
&#xD;
          -  Adequate kidney function (calculated creatinine clearance &gt;40 mL/min)&#xD;
&#xD;
          -  Negative serum or urine pregnancy test within 2 to 7 days prior to the start of study&#xD;
             treatment in females of childbearing potential&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing and able to use an&#xD;
             adequate method of contraception to avoid pregnancy for the duration of the study in&#xD;
             such a manner that the risk of pregnancy is minimized. Acceptable contraceptives&#xD;
             include intra-uterine devices (IUDs), hormonal contraceptives (oral, depot, patch, or&#xD;
             injectable) and double barrier methods such as condoms or diaphragms with spermicidal&#xD;
             gel or foam.&#xD;
&#xD;
          -  Signed informed consent form (ICF), minor assent form (if applicable), prior to start&#xD;
             of any study-specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active serious infection not controlled by oral or intravenous antibiotics&#xD;
&#xD;
          -  Treatment with any investigational antileukemic agent or chemotherapy agent in the&#xD;
             last 7 days prior to study entry and lack of full recovery from side effects due to&#xD;
             prior therapy independent of when that therapy was given&#xD;
&#xD;
          -  Rapidly progressive disease with compromised organ function judged to be&#xD;
             life-threatening by the Investigator&#xD;
&#xD;
          -  Patients with clinical evidence of active central nervous system (CNS) disease&#xD;
&#xD;
          -  Concurrent treatment with other anticancer agents&#xD;
&#xD;
          -  Pregnant and/or lactating female&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) infection HIV testing will be&#xD;
             performed at the Screening visit for patients who have not been tested within 6 months&#xD;
             of receiving study drug, as well as those patients who have had exposure or have been&#xD;
             transfused with blood products that were not appropriately screened.&#xD;
&#xD;
          -  Patients with known active hepatitis B and/or hepatitis C infection Hepatitis testing&#xD;
             will be performed at the Screening visit for patients who have not been tested within&#xD;
             6 months of receiving study drug, as well as those patients who have had exposure or&#xD;
             have been transfused with blood products that were not appropriately screened.&#xD;
&#xD;
          -  Hypersensitive or intolerant to any component of the study drug formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell</keyword>
  <keyword>leukemia</keyword>
  <keyword>B-lymphoblastic leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>B-All</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

